Tuesday, May 21, 2013 Last update: 7:07 AM
Company Tech News as it Breaks
Trade Events
Pfizer Inc.
News articles for Pfizer Inc.:
Monday, May 20, 2013
- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to FutilityPfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients ... read more
Monday, May 13, 2013
- Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual MeetingPfizer Inc. (NYSE: PFE) announced today that 11 abstracts for tofacitinib will be presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting being held June 12-15 ... read more
Tuesday, April 30, 2013
- Pfizer Reports First-Quarter 2013 ResultsPfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2013 and updated certain components of its 2013 financial guidance to reflect the impact of recent changes in foreign ... read more
Sunday, April 28, 2013
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 YearsPfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in ... read more
Thursday, April 25, 2013
- Pfizer Hosts Annual Meeting Of ShareholdersThe board of directors of Pfizer Inc. today declared a 24-cent second-quarter 2013 dividend on the company’s common stock, payable June 4, 2013, to shareholders of record at ... read moreTop-Line Data Show Celecoxib Met Primary Objective In Clinical Trial To Evaluate The Effects On Blood Pressure In Pediatric Patients With Juvenile Idiopathic ArthritisPfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 4 clinical trial in which the primary objective was to measure blood pressure (hypertension) among pediatric patients ... read more
Thursday, April 18, 2013
- Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of ShareholdersPfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April ... read more
Wednesday, April 10, 2013
- Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast CancerPfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by ... read more
Thursday, March 28, 2013
- Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European CommissionPfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF® (bosutinib) in the European Union (EU) for the treatment of adult patients ... read more
Tuesday, March 26, 2013
- Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with AnalystsPfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, ... read more
Monday, March 25, 2013
- XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ® (tofacitinib citrate) for the treatment of adults with rheumatoid ... read more
Monday, March 4, 2013
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13® In Adults With HIVPfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 ... read more
Thursday, February 21, 2013
- Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset SeizuresPfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 3 study that showed Lyrica® (pregabalin) Capsules CV were as effective as levetiracetam as an adjunctive therapy ... read more
Tuesday, February 19, 2013
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at ... read more
Friday, February 1, 2013
- Pfizer Inc. Issues Statement on ZoetisTM IPOPfizer Inc. (NYSE: PFE) today announced that its former animal health business unit, now a standalone company named ZoetisTM, began trading on the New York Stock Exchange under ... read more
Thursday, January 31, 2013
- Pfizer Wins RAPAMUNE® Patent Case in Delaware District CourtPfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer’s patent covering a method for using sirolimus, the active ingredient ... read more
Tuesday, January 29, 2013
- Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial GuidancePfizer Inc. (NYSE: PFE): ($ in millions, except per ... read more
Friday, January 25, 2013
- Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal DiseasePfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company’s pneumococcal conjugate vaccine, Prevnar 13®* ... read more
Thursday, January 24, 2013
- Study Shows Higher Dose Of Toviaz® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive BladderPfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) 8 mg once daily in patients with overactive ... read moreCHANTIX® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIXPfizer Inc. (NYSE: PFE) announced today that a post-marketing study assessing the efficacy and safety of varenicline (CHANTIX®/CHAMPIX®) in a population of smokers who had made a previous ... read more